Observed Signal · Sep 22, 2026 · Market Signal · Source: AbbVie · Impact: 2/5
AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued
On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...
Track AbbVie Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Apheris and Ginkgo Launch Antibody Developability Consortium
Berlin-based Apheris and Ginkgo Bioworks' Ginkgo Datapoints have launched the Antibody Developability Consortium, an industry collaboration to build the largest standardized antibody developability dataset. Founding members include AbbVie, argenx, Lundbeck, and Takeda, who will contribute proprietary antibody sequences. The consortium aims to train AI models on 10,000 antibodies using Apheris's federated data infrastructure, which allows members to train and refine models without exposing proprietary data. Ginkgo Datapoints will lead scientific design and execution, while Apheris provides the secure environment for model training. The initial dataset is expected by early 2027. This initiative addresses the lack of large, standardized datasets for predicting antibody manufacturability and developability, potentially reducing development time and costs for pharmaceutical companies.
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...
REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy
REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.